Corvus Pharmaceuticals, Inc.
CRVS Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$10.54
KIRA · Stoqly’s AI analyst, in plain words
- Corvus Pharmaceuticals, Inc. lost $15.3M in fiscal 2025.
- Free cash flow was −$33.0M in fiscal 2025, — of revenue.
Market cap
$974M
P/E
—
Revenue
—
Net income
−$15.3M
Free cash flow
−$33.0M
Operating margin
—
Corvus Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$15.3M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Corvus Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Corvus Pharmaceuticals, Inc.
- CIK
- 0001626971
Corvus Pharmaceuticals, Inc. · CRVS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$43.2M | −$41.3M | −$27.0M | −$62.3M | −$15.3M |
| Diluted EPS | −$1.03 | −$0.89 | −$0.56 | −$1.02 | −$0.53 |
| Cash | |||||
| Cash from operations | −$36.7M | −$27.0M | −$23.9M | −$25.4M | −$32.8M |
| Capital expenditure | $0.0M | $0.3M | $0.0M | — | $0.2M |
| Free cash flow | −$36.7M | −$27.3M | −$24.0M | — | −$33.0M |
| Share count change | 42.0% | 11.2% | 3.2% | 27.0% | 30.8% |
| Debt and strength | |||||
| Cash and short-term investments | $63.5M | $13.2M | $12.6M | $52.0M | $56.8M |
| Shareholders' equity | $97.2M | $56.1M | $38.7M | $32.6M | $61.2M |
| Current ratio | 7.4x | 4.1x | 4.1x | 1.5x | 6.2x |
| Returns and quality | |||||
| Return on equity | −51.1% | −53.9% | −57.0% | −174.9% | −32.6% |
| Return on tangible equity | −44.5% | −73.6% | −69.9% | −191.3% | −25.0% |
| Altman Z'' | 1.7 | −9.9 | −18.5 | −18.7 | −12.0 |
Insiders bought, 12 months
$0.3M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Corvus Pharmaceuticals, Inc. · CRVS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.54 a share, the company is worth $974M.
Source: SEC EDGAR XBRL filings (CIK 0001626971). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.